Form 4: RA Capital Increases Stake in Acrivon Therapeutics

RA Capital Management acquired 3,888,888 shares of Acrivon Therapeutics at $1.80 per share.

Summary

• RA Capital Management, L.P. reported the acquisition of 3,888,888 shares of Acrivon Therapeutics, Inc. (ACRV) common stock.
• The transaction occurred on April 22, 2026, at a price of $1.80 per share.
• Following this transaction, the reporting entities beneficially own 11,803,094 shares held by the Fund and 426,302 shares held by the Nexus Fund II.
• The reporting persons include RA Capital Management, L.P., RA Capital Healthcare Fund L.P., RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev Shah.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive signal, as significant insider/institutional buying typically reflects strong internal conviction in the company's valuation and future clinical progress.

Positives

• Significant increase in equity position by a major institutional investor, signaling confidence in the company's long-term prospects.
• The acquisition of nearly 3.9 million shares demonstrates strong financial backing from a specialized healthcare investment firm.

Negatives

• None identified in this filing.

Risks

• The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest, which is standard for institutional investment structures.

Future Outlook

The filing does not contain forward-looking statements regarding company operations, but reflects the continued investment commitment of a major shareholder.

Management Comments

• The reporting persons disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that institutional accumulation of biotech equities, particularly by specialized firms like RA Capital, often precedes or follows significant clinical milestones or capital raises, indicating a strategic alignment with the company's development pipeline.

Comparison to Industry Standards

• The transaction size is consistent with typical institutional follow-on investments in small-cap biotechnology firms.
• The involvement of RA Capital as a 10% owner and board-represented entity is standard for venture-backed life sciences companies.

Related Party Transactions

• Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

Stakeholder Impact

• Shareholders may view the increased institutional stake as a vote of confidence, potentially stabilizing the share price.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership by RA Capital.
• Observation of potential future clinical trial updates from Acrivon Therapeutics.

Key Dates

Recommendation

Institutional accumulation by a specialized healthcare fund like RA Capital often serves as a bullish indicator for biotech stocks, suggesting that sophisticated investors see value at the current price point.

Keywords

Acrivon Therapeutics, ACRV, RA Capital Management, Form 4, Insider Trading, Biotech Investment, Institutional Ownership